EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation

Jeong Eun Kang, Hyun Wook Seo iD, Dong-Eun Kim, Young Hyun Shin, Songmee Bae, Cheol-Hee Yoon iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0322962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Jeong Eun Kang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Chronic Viral Disease Research, Center for Emerging Virus Research, National Institute of Health, Cheongju, Republic of Korea. Hauptthemen laut MEDLINE: HIV-1, Aniline Compounds, Virus Latency, Virus Activation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human immunodeficiency virus-1 (HIV-1) is a hazardous pathogen responsible for causing acquired immunodeficiency syndrome (AIDS). HIV-1 provirus survives in latently infected cells for a long time, despite treatment with combinational anti-retroviral therapy (cART); therefore, it is considered as a major obstacle in HIV-1 treatment. Several strategies have been developed to selectively eliminate latently HIV-1-infected cells; however, clinical success has not yet been reported. Here, we identified several key factors associated with cell apoptosis, which were upregulated in latently infected cells. Subsequently, we screened compounds targeting these factors to selectively kill latently HIV-1-infected cells. Among these, ABT-263 (Navitoclax), a BCL-2 inhibitor, exhibited a potent and selective killing effect on latently HIV-1-infected cells and exerted synergistic effects with combinations of other compounds targeting myeloid cell leukemia-1 (MCL-1), X-linked inhibitor of apoptosis protein (XIAP), and BAX. In an ex vivo model, latently HIV-1-infected memory CD4 + T cells were efficiently eliminated via treatment with ABT-263 alone and its combinations with other modulatory compounds. Taken together, our results demonstrate that the balance of pro- and anti-apoptotic factors is crucial for the survival of latently HIV-1-infected cells. Thus, disrupting this balance using ABT-263 or combinations having ABT-263 without proviral reactivation may be useful for developing a novel strategy to eliminate latently infected cells in individuals infected with HIV-1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1Aniline CompoundsVirus LatencyVirus ActivationProto-Oncogene Proteins c-bcl-2SulfonamidesHIV InfectionsAnti-HIV AgentsHumansApoptosisCD4-Positive T-LymphocytesMyeloid Cell Leukemia Sequence 1 Proteinbcl-2-Associated X Protein

Substanzen

navitoclaxAniline CompoundsProto-Oncogene Proteins c-bcl-2SulfonamidesAnti-HIV AgentsMyeloid Cell Leukemia Sequence 1 Proteinbcl-2-Associated X Protein

Autor:innen und Institutionen

  • Division of Chronic Viral Disease Research, Center for Emerging Virus Research, National Institute of Health, Cheongju, Republic of Korea.

ORCID-Profile: Hyun Wook Seo, Cheol-Hee Yoon

Förderung

  • Korea National Institute of Health

Zitieren

APA

Kang, J. E., Seo, H. W., Kim, D. E., Shin, Y. H., Bae, S., & Yoon, C. H. (2025). ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation. PLOS One. https://doi.org/10.1371/journal.pone.0322962

Vancouver

Kang JE, Seo HW, Kim DE, Shin YH, Bae S, Yoon CH. ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation. PLOS One. 2025. doi:10.1371/journal.pone.0322962

BibTeX
@article{Kang2025,
  author = {Kang, Jeong Eun and Seo, Hyun Wook and Kim, Dong-Eun and Shin, Young Hyun and Bae, Songmee and Yoon, Cheol-Hee},
  title = {ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0322962}
}
Kostenlos starten →